Rein Therapeutics, Inc. Cash Flow Statement
RNTX|9 years of annual SEC 10-K data (FY2017-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 9 fiscal years. All figures from audited SEC 10-K filings.
Rein Therapeutics, Inc. used $22M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$62.9M | -$15.7M | -$27.3M | -$27.3M | -$21.2M | -$29.4M | -$31.5M | -$22.6M | -$12.9M |
| Depreciation & Amortization | $63.0K | $119.0K | $169.0K | $121.0K | $163.0K | $155.0K | $218.0K | $129.0K | $325.0K |
| Operating Cash Flow | -$22.3M | -$19.8M | -$24.9M | -$23.8M | -$20.5M | -$26.5M | -$27.9M | -$20.5M | -$11.7M |
| Capital Expenditures | - | - | - | $157.0K | $5.0K | $151.0K | $4.4M | $142.0K | $94.0K |
| Free Cash Flow | - | - | - | -$23.9M | -$20.5M | -$26.6M | -$32.3M | -$20.7M | -$11.8M |